[1] Chang J, Liu X, Sun Y. Mortality due to acute myocardial infarction in China from 1987 to 2014: Secular trends and age-period-cohort effects. Int J Cardiol, 2017; 227, 229−38. doi:  10.1016/j.ijcard.2016.11.130
[2] The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on Cardiovascular Health and Diseases in China 2021: An updated summary. Biomed Environ Sci, 2022; 35, 573−603.
[3] Li J, Li X, Ross JS, et al. Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study. Eur Heart J Acute Cardiovasc Care, 2017; 6, 232−43. doi:  10.1177/2048872615626656
[4] China Chest Pain Center Alliance, China Cardiovascular Health Alliance et al. Summary of the China chest pain center quality control Report (2021). Chin J Intervent Cardiol, 2022; 30, 321−7. (In Chinese
[5] Feng L, Li M, Xie W, et al. Prehospital and in-hospital delays to care and associated factors in patients with STEMI: an observational study in 101 non-PCI Hospitals in China. BMJ Open, 2019; 9: e031918. doi:  10.1136/bmjopen-2019-031918
[6] Li GX, Zhou B, Qi GX, et al. Current trends for ST-segment elevation myocardial infarction during the Past 5 Years in rural areas of China's Liaoning province: a multicenter study. Chin Med J (Engl), 2017; 130, 757−66. doi:  10.4103/0366-6999.202742
[7] Zhang Y, Wang S, Cheng Q, et al. Reperfusion strategy and in-hospital outcomes for ST elevation myocardial infarction in secondary and tertiary hospitals in predominantly rural central China: a multicentre, prospective and observational study. BMJ Open, 2021; 11, e053510. doi:  10.1136/bmjopen-2021-053510
[8] Xu HY, Yang YJ, Wang CS, et al. Association of hospital-level differences in care with outcomes among patients with acute ST-segment elevation myocardial infarction in China. JAMA Netw Open, 2020; 3, e2021677. doi:  10.1001/jamanetworkopen.2020.21677
[9] Xu HY, Li W, Yang JG, et al. The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China. Am Heart J, 2016; 175, 193-201. e3. doi:  10.1016/j.ahj.2015.04.014
[10] Sun H, Yang YJ, Xu HY, et al. Survey of medical care resources of acute myocardial infarction in different regions and levels of hospitals in China. Chin J Cardiol, 2016; 44, 565−9. (In Chinese
[11] Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Glob Heart, 2012; 7, 275−95. doi:  10.1016/j.gheart.2012.08.001
[12] Chinese Society of Cardiology of Chinese Medical Association, Editorial board of Chinese Journal of Cardiology. Guideline for diagnosis and treatment of patients with ST-elevation myocardial infarction. Chin J Cardiol, 2010; 38, 675−690. (In Chinese
[13] Shavadia J, Ibrahim Q, Sookram S, et al. Bridging the gap for nonmetropolitan STEMI patients through implementation of a pharmacoinvasive reperfusion strategy. Canad J Cardiol, 2013; 29, 951−9. doi:  10.1016/j.cjca.2012.10.018
[14] Masuda J, Kishi M, Kumagai N, et al. Rural-urban disparity in emergency care for acute myocardial infarction in Japan. Circ J, 2018; 82: 1666−74. doi:  10.1253/circj.CJ-17-1275
[15] Hillerson D, Li S, Misumida N, et al. Characteristics, process metrics, and outcomes among patients with ST-elevation myocardial infarction in rural vs urban areas in the US: a report from the US national cardiovascular data registry. JAMA Cardiol, 2022; 7, 1016−24. doi:  10.1001/jamacardio.2022.2774
[16] Yin XJ, He YB, Zhang J, et al. Patient-level and system-level barriers associated with treatment delays for ST elevation myocardial infarction in China. Heart, 2020; 106, 1477−82. doi:  10.1136/heartjnl-2020-316621
[17] Wu C, Zhang XY, Yu M, et al. Analysis of in-hospital outcome of patients with ST-segment elevation myocardial infarction undergoing various thrombolytic strategies in China. Chin Circulat J, 2021; 36, 1070−76. (In Chinese
[18] Borgia F, Goodman SG, Halvorsen S, et al. Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. Eur Heart J, 2010; 31, 2156−69. doi:  10.1093/eurheartj/ehq204
[19] D'Souza SP, Mamas MA, Fraser DG, et al. Routine early coronary angioplasty versus ischaemia-guided angioplasty after thrombolysis in acute ST-elevation myocardial infarction: a meta-analysis. Eur Heart J, 2011; 32, 972−82. doi:  10.1093/eurheartj/ehq398
[20] Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2017; 39, 119−77.
[21] Larson DM, Duval S, Sharkey SW, et al. Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. Eur Heart J, 2012; 33, 1232−40. doi:  10.1093/eurheartj/ehr403
[22] Zhang Y, Yu B, Han Y, et al. Protocol of the China ST-segment elevation myocardial infarction (STEMI) Care Project (CSCAP): a 10-year project to improve quality of care by building up a regional STEMI care network. BMJ Open, 2019; 9, e026362. doi:  10.1136/bmjopen-2018-026362
[23] National Health Commission of the People’s Republic of China. China public health statistical yearbook 2020. Beijing: Peking Union Medical College Publishing House. 2021. (In Chinese
[24] Huber K, Gersh BJ, Goldstein P, et al. The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions. Eur Heart J, 2014; 35, 1526−32. doi:  10.1093/eurheartj/ehu125
[25] West RM, Cattle BA, Bouyssie M, et al. Impact of hospital proportion and volume on primary percutaneous coronary intervention performance in England and Wales. Eur Heart J, 2011; 32, 706−11. doi:  10.1093/eurheartj/ehq476
[26] Doll JA, Nelson AJ, Kaltenbach LA, et al. Percutaneous coronary intervention operator profiles and associations with in-hospital mortality. Circul Cardiovascul Intervent, 2022; 15, e010909. doi:  10.1161/CIRCINTERVENTIONS.121.010909
[27] Danchin N, Coste P, Ferrières J, et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardial infarction (FAST-MI). Circulation, 2008; 118, 268−76. doi:  10.1161/CIRCULATIONAHA.107.762765
[28] Stenestrand U, Lindbäck J, Wallentin L, et al. Long-term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction. JAMA, 2006; 296, 1749−56. doi:  10.1001/jama.296.14.1749
[29] Ross AM, Gao RL, Coyne KS, et al. A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial. Am Heart J, 2001; 142, 244−7. doi:  10.1067/mhj.2001.116963